Preferences help
enabled [disable] Abstract
Number of results
2009 | 81 | 10 | 457-464
Article title

Jun Gene Expression is Decreased in Parathyroid Adenoma

Title variants
Languages of publication
The aim of the study was to analyze the gene expression of JUN and CCND1 in a group of parathyroid tissues obtained from patients with primary hyperparathyroidism in comparison to hyperplastic parathyroid and normal/atrophic parathyroid tissues by real-time quantitative PCR. Our goal was to validate the conclusion of Forsberg et al (2005) who reported overexpression of JUN in parathyroid adenomas by a joint microarray and QPCR study.Material and methods. The analysis of JUN, CCND1 was carried out by QPCR in 14 parathyroid adenomas, 8 hyperplasia cases and 50 normal/atrophic parathyroid samples taken intraoperatively. Expression of the examined genes was normalized to the reference index (geometric mean of reference genes expression: EIF3S10, UBE2D2, ATP6V1E).Results. We observed a decrease of JUN expression in parathyroid adenomas in comparison to both normal/atrophic and hyperplastic parathyroids. The fold change value was 0.71 in comparison of adenomas to normal/atrophic samples (p = 0.044) and 0.75 to hyperplastic glands (p = 0.003). For CCND1 we observed one case of parathyroid adenoma with a very clearly increased expression, while 3 adenomas (21.4% of all adenomas) exhibited the increase over the highest value seen in normal parathyroids (fold change = 3.52).Conclusions. In parathyroid adenomas we were not able to confirm any overexpression of JUN gene, as suggested by the previous study. On the contrary, we observed a distinct inhibition of JUN RNA expression in comparison to non-neoplastic parathyroids. For CCND1 gene overexpression in parathyroid adenomas, we report the frequency of 21.4%.
Physical description
1 - 10 - 2009
25 - 11 - 2009
  • Shane E: Parathyroid carcinoma. J Clin Endocrinol Metab 201; 86: 485-93.
  • Forsberg L, Björck E, Hashemi J et al.: Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology. Eur J Endocrinol 2005; 152: 459-70.
  • Palanisamy N, Imanishi Y, Rao PH et al.: Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clinic Endocrinol and Metabol 1998; 83: 1766-70.
  • Farnebo F, Kytola S, Teh BT et al.: Alternative genetic pathways in parathyroid tumorigenesis. J Clinic Endocrinol and Metabol 1999; 843: 775-80.
  • Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-57
  • Karin M, Liu Z, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 1997; 9: 240-46.[Crossref][PubMed]
  • Jochum W, Passegue E, Wagner EF: AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20: 2401-12.[PubMed][Crossref]
  • Eferl R, Ricci R, Kenner L et al.: Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003; 112: 181-92.
  • Maeno K, Masuda A, Yanagisawa K et al.: Altered regulation of c-jun and its involvement in anchorage-independent growth of human lung cancers. Oncogene 2006; 12; 25(2): 271-77.
  • Dass CR, Khachigian LM, Choong PF: c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Mol Cancer Res 2008; 6(8): 1289-92.[WoS][Crossref]
  • Dass CR, Galloway SJ, Clark JC et al.: Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther 2008; 7(8): 1302-04.[WoS]
  • Changmeng Cai, Chen-Lin Hsieh Lirim Shemshedini.: c-Jun Has Multiple Enhancing Activities in the Novel Cross Talk between the Androgen Receptor and Ets Variant Gene 1 in Prostate Cancer. Mol Cancer Res 2007; 5, 725-35.[WoS]
  • Tashiro E, Tsuchiya A, Imoto M: Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007; 98(5): 629-35.[Crossref][PubMed]
  • Fu M, Wang C, Li Z et al.: Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145: 5439-47.
  • Nishida N, Fukuda Y, Komeda T et al.: Amplifcation and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Research 1994; 54: 3107-10.
  • JiangW, Kahn SM, Tomita N et al.: Amplifcationand expression of human cyclin D gene in oesophageal cancer. Cancer Research 1992; 2: 2980-83.
  • Arnold A, Shattuck TM, Mallya SM et al.: Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2: N30-6.[PubMed]
  • Hosokawa Y, Arnold A: Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer 1998; 22: 66-71.
  • Vandesompele J, De Preter K, Pattyn F et al.: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034
  • Haven CJ, Howell VM, Eilers P et al.: Gene expression of parathyroid tumors: molecular sub-classification and identification of the potential malignant phenotype. Cancer Research 2004; 64: 7405-11.[Crossref]
  • Vasef MA, Brynes RK, Sturm M et al.: Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 1999; 12: 412-16.[PubMed]
  • Hsi ED, Zukerberg LR, Yang WI et al.: Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996; 81: 1736-39.
  • Yi Y, Nowak NJ, Pacchia AL et al.: Chromosome 11 genomic changes in parathyroid adenoma and hyperplasia: array CGH, FISH and microarrays. Genes Chromosome Cancer 2008; 47(8): 639-48.[WoS]
  • Mallya SM, Gallagher JJ, Wild YK et al.: Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model hyperparathyroidism. Mol Endocrinol 2005; 19(10): 2603-09.[Crossref]
  • Corbetta S, Eller-Vainicher C, Vicentini L et al.: Modulation of cyclin D1 expression in human tumoral parathyroid cells: effects of growth factors and calcium sensing receptor activation. Cancer Letters 2007; 255: 34-41.[WoS]
  • Woodard GE, Lin L, Zhang JH et al.: Parafibromin, product of the hyperparathyroidism-jaw tumor, regulates cyclin D1/PRAD1 expression. Oncogene 2005; 24(7): 1272-76.
  • Juhlin C, Larsson C, Yakoleva T et al.: Loss of parafibromin in a subset of parathyroid adenomas. Endocrine-Related Cancer 2006; 13: 509-23.[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.